SLx-4090

Research use only, not for human use.

A novel potent, selective and orally active enterocytic microsomal triglyceride transfer protein (MTP) inhibitor that inhibits only MTP localized to enterocytes with IC50 of 6 nM.

A novel potent, selective and orally active enterocytic microsomal triglyceride transfer protein (MTP) inhibitor that inhibits only MTP localized to enterocytes with IC50 of 6 nM; inhibits apolipoprotein B (IC50=9.6 nM) but not apolipoprotein A1 secretion in Caco-2 cells, reduces postprandial lipids in rats with ED50 of 7mg/kg, decreases the body weight gain and increases HDL-C in ApoE(?/?) mice.Dyslipidemia Phase 2 Clinical.

SLX-4090 inhibits apolipoprotein B (IC50 value 9.6 nM) but not apolipoprotein A1 secretion in Caco-2 cells.

SLX-4090 (orally, 30 mg/kg) reduces postprandial lipids by 50% with an ED50 value 7 mg/kg in rats.

SLx 4090 | SLx4090

Membrane Transporter/Ion Channel

MTP

MTP

Cardiovascular Disease

Dyslipidemia

913541-47-6

546.546

C31H25F3N2O4

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (182.97 mM)

O=C(N1CC2=C(C=C(NC(C3=CC=CC(OC)=C3C4=CC=C(C(F)(F)F)C=C4)=O)C=C2)CC1)OC5=CC=CC=C5

6-(4'-Trifluoromethyl-6-methoxy-biphenyl-2-ylcarboxamido)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid phenyl ester

(-20℃)

With Ice Pack

≥ 2 years